Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study. ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 230 | Alveolar hypoventilation syndrome | 1 |
230. Alveolar hypoventilation syndrome
Clinical trials : 8 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 18 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01964339 (ClinicalTrials.gov) | October 9, 2013 | 14/10/2013 | Obesity Hypoventilation Syndrome Prevalence Study | Obesity Hypoventilation Syndrome Prevalence Study | Obesity Hypoventilation Syndrome | Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.;Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study. | Philips Respironics | NULL | Terminated | 21 Years | N/A | All | 44 | United States |